Clinical Trial

Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)

Name: Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study) — clinical trial record (NCT07347197)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EMERALD

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The purpose of this clinical study is to evaluate the safety and efficacy of endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction for 26 weeks after transplantation.

Trial Details

NCT Number	NCT07347197
Lead Sponsor	Heartseed Inc.
Conditions	Heart Failure, Ischemic Heart Failure, Ischemic Heart Disease, Dilated Cardiomyopathy (DCM)
Enrollment	14 participants
Start Date	2026-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2030-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-16